Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics
Authors' conclusion
An expanded ACPA profile appears to be more strongly associated with biologic treatment response in RA than commercially available anti-CCP3 antibody levels.
Study context
- Population
- Patients with RA initiating biologics in a prospective observational RA cohort; ACPAs to 25 citrullinated peptides measured in banked enrolment serum
- Participants
- 1,092 patients
- Exposure
- ACPA profile principal component (PC) score quartiles and anti-CCP3 antibody category, associated with EULAR response to biologics
- Outcome
- EULAR (good/moderate/none) treatment response
- Follow-up
- 6 months
Methodological detailsnon-randomized, observational, sub-study, adjusted ordinal regression, principal component analysis
- Non-randomized
- Observational
- Sub-study
- Adjusted ordinal regression
- Principal component analysis
Main finding
As reported in the abstract
EULAR treatment response by PC score (highest quartile)
Odds ratio (95% CI)
PC1 highest quartile
1.76(1.22–2.53)
PC2 highest quartile
1.74(1.23–2.46)
Observational data: associations, not effects.
Further findings
Moderate/good EULAR response (whole cohort) · 6 months
- Achieved moderate/good EULAR response
- 68.5%
Interaction between PCs and treatment group in EULAR responses
- No evidence of interaction
- P for interaction > 0.1
Original publication
Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford). Published 30 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →